Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025 BPTH_Corporate_Update_Conference_Call_Announcement_20250522
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients BP1001-A_Obesity_Third_Efficacy_Milestone